Researchers discovered that ALPK2, a heart-specific enzyme, may protect against HFpEF by activating TPM1 in heart muscle ...

What is ALPK2, and how can it help treat heart failure? Researchers have found that this heart-specific enzyme may prevent ...

Tectonic Therapeutic, Inc.'s stock surged 120% on positive Phase 1b data for TX45 in treating PH-HFpEF, offering a potential ...

Tatsuya Yoshida, Mikito Takefuji, and Toyoaki Murohara in the Department of Cardiology, Nagoya University Graduate School of Medicine, identified an enzyme, alpha-kinase 2 (ALPK2) that is specifically ...

Background Early heart failure (HF) diagnosis is crucial to ensure that optimal guideline-directed medical therapy (GDMT) is ...

The company shared interim results from an ongoing Phase II trial examining its recombinant antibody fusion protein.

According to GlobalData, Phase II drugs for Diastolic Heart Failure (HFpEF ... It is investigating JK07, a recombinant fusion protein medicine targeting heart failure with reduced ejection fraction.

The study investigates the prognostic impact of sex and sex‐related differences in patients hospitalized with heart failure with mildly reduced ejection fraction (HFmrEF). More data regarding the ...

Increased myocardial stiffness is a major cause of LV diastolic dysfunction ... N2B is related to HFNEF. In a healthy heart the normal N2BA:N2B ratio is approximately 30:70, but in patients ...

Left ventricular diastolic ... ejection fraction (EF) greater than 50%. T2DM was defined according to the 2023 ADA Standards of Care in Diabetes (12). The following criteria were used for exclusion: ...

Heart failure with preserved ejection fraction is a heterogeneous syndrome ... and objective evidence of left ventricular diastolic dysfunction or raised left ventricular filling pressures.